Cost-Effectiveness Of Idelalisib In Combination With Rituximab For The Treatment Of Relapsed/Refractory Chronic Lymphocytic Leukemia (Cll) In Portugal.
نویسندگان
چکیده
TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGAL Gouveia M1, Silva MG2, Alarcão J3, Fiorentino F 3, Carda J 4, Costa R 5, Mariz JM 6, Raposo J 7, Costa J 7, Borges M 8 1Católica Lisbon School of Business and Economics, Lisbon, Portugal, 2Instituto Português Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal, 3Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 4Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, 5Hospital Garcia de Orta, Almada, Portugal, 6Instituto Português de Oncologia do Porto Francisco Gentil, Oporto, Portugal, 7Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 8Institute of Molecular Medicine, Lisbon, Portugal
منابع مشابه
Management of chronic lymphocytic leukemia.
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) is usually diagnosed in asymptomatic patients with early-stage disease. The standard management approach is careful observation, irrespective of risk factors unless patients meet the International Workshop on CLL (IWCLL) criteria for "active disease," which requires treatment. The initial standard therapy for most patients combines a...
متن کاملTargeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival (OS) in untreated fit patients; humanized anti-CD52 antibody alemtuzumab and fully human anti-CD20 antibody ofatumumab lead to improvement in ...
متن کاملIdelalisib: Practical Tools for Identifying and Managing Adverse Events in Clinical Practice
Idelalisib is a first-in-class oral selective inhibitor of phosphatidylinositol 3-kinase delta, which is selectively expressed in hematopoietic cells, where it is critical to B-cell receptor signaling and B-cell development and function. Idelalisib is approved in the United States for the treatment of relapsed chronic lymphocytic leukemia (CLL; in combination with rituximab), relapsed follicula...
متن کاملIdelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Idelalisib [Zydelig (Gilead Sciences, Inc.), also known as CAL-101 and GS-1101] was approved in 2014 in the United States and European Union for the treatment of three indolent B-cell neoplasms: relapsed/refractory chronic lymphocytic leukemia (CLL, in combination with rituximab), relapsed follicular lymphoma, and relapsed small lymphocytic lymphoma (as monotherapy). Furthermore, it was approve...
متن کاملVIII. Treatment of chronic lymphocytic leukaemia, where are we heading?
The past year has seen enormous changes in the treatment of chronic lymphocytic leukaemia (CLL), partly based on the approval of several new molecules. In fact, the American Society of Clinical Oncology (ASCO) named CLL therapies the ‘the Cancer advance of the year’ in its annual report of January 2015. This was the first time that ASCO singled out a particular advance in cancer treatment in it...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 18 7 شماره
صفحات -
تاریخ انتشار 2015